Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore
Open Access
- 1 June 2015
- journal article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. ume 11, 303-310
- https://doi.org/10.2147/vhrm.s82710
Abstract
Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore Sajita Setia,1 Selwyn Sze-Wang Fung,2 David D Waters3 1Medical Affairs, Pfizer Pte Ltd, Singapore; 2Regional Medical Affairs, Pfizer Pte Ltd, Hong Kong; 3Department of Medicine, University of California, San Francisco, CA, USA Purpose: There is an unmet need for strategies to prevent atherosclerotic cardiovascular disease in Singapore. The main objective of this study was to investigate Singapore physicians’ response to the 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines for treatment of cholesterol and their impact on clinical practice. Methods: This survey was conducted in two stages, qualitative and quantitative. Physicians were initially screened on the basis of an initial screener questionnaire, and eligible physicians were then included in the study. Results: Qualitative (n=19) and quantitative (n=66) surveys were completed by eligible physicians from Singapore. Physicians were less familiar with the 2013 ACC/AHA guidelines (35%) as compared with the Singapore Ministry of Health (MoH) lipid guidelines 2006 (49%). Of the physicians whose opinion was sought on the ACC/AHA guidelines, more than 50% disagreed with the definition of high-, moderate-, and low-intensity statin therapy; recommendation of atorvastatin 40–80 mg and rosuvastatin 20–40 mg as medications for high-intensity statin therapy; and classification of individuals who would benefit from moderate- to high-intensity statin therapy. Most physicians assumed that Asians may be intolerant to high-intensity statin therapy. Conclusion: Although embracing the 2013 ACC/AHA guidelines in clinical practice is expected to provide better clinical care to patients, our study revealed high reluctance by physicians, especially in the use of high-dose statins. However, ACC/AHA guidelines can be easily adopted in Asia as there is a wealth of data available for atorvastatin in primary and secondary prevention of atherosclerotic cardiovascular disease with similar efficacy and safety profiles in the white and Asian populations. Keywords: cholesterol treatment, cardiovascular disease, statin therapy, CVD risk factors, LDL target levelsKeywords
This publication has 21 references indexed in Scilit:
- Statins and the kidney: friend or foe?The Lancet Diabetes & Endocrinology, 2015
- Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trialThe Lancet Diabetes & Endocrinology, 2015
- Cardiovascular Disease Epidemiology in AsiaCirculation Journal, 2013
- Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IVIndian Journal of Endocrinology and Metabolism, 2013
- Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular DiseaseClinical Medicine Insights: Cardiology, 2012
- Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) studyCurrent Medical Research and Opinion, 2008
- Epidemiology of dyslipidemia and economic burden on the healthcare system.2007
- Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular EventsDrugs, 2007
- Epidemic obesity and type 2 diabetes in AsiaThe Lancet, 2006
- Nutritional mechanisms that influence cardiovascular diseaseThe American Journal of Clinical Nutrition, 2006